

jc447 U.S. PTO
01/20/99

Please type a plus sign (+) inside this box ☐

Attorney Docket P1085R4-1A
PATENT

CERTIFICATION UNDER 37 CFR 1.10

EM168882496US: Express Mail Number

January 20, 1999: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Yvonne E. Carter

jc549 U.S. PTO
09/23/182
01/20/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Vanessa Hsei
Iphigenia Koumenis
Steven Leong
Leonard Presta
Zahra Shahrokh
Gerardo Zapata

Title: **ANTIBODY FRAGMENT-POLYMER CONJUGATES AND HUMANIZED ANTI-IL-8
MONOCLONAL ANTIBODIES**

1. Type of Application

[] This application is for an original, non-provisional application.

[X] This application is a non-provisional application filed under 37 CFR 1.53(b), claiming priority under 35 USC 119(e) to provisional application numbers 60/074,330 filed 22 January 1998; 60/094,013 filed 24 July 1998; 60/094,003 filed 24 July 1998; and 60/075,467 filed 20 February 1998, the contents of which are incorporated herein by reference.

[] This is a [] continuation-in-part [] continuation [] divisional application claiming priority to application Serial Number ___, filed ___, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)
(Non-provisional)**

299 pages of specification
5 pages of claims

1 page(s) of abstract
142 sheet(s) of drawings
[] formal [x] informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

X An unexecuted declaration of the inventor(s) [X] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

___ A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

___ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

X An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.

(for cont./div.)

___ The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

___ Cancel in this application original claims __ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

___ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

___ Amend the specification by inserting before the first line the sentence:

--This is a

___ non-provisional application
___ continuation
___ divisional
___ continuation-in-part

of co-pending applications

_____ Serial No. _____ filed on _____ filed, _____ and which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

_____ International Application _ filed on ___ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$760.00
Total Claims	35	- 20 =	15	X \$18.00	\$270.00
Independent Claims	1	- 3 =	0	X \$78.00	\$0.00
_____ Multiple dependent claim(s), if any				+ \$260.00	\$0.00
Filing Fee Calculation					\$1,030.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,030.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☒ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other:

10. **Maintenance of Copendency of Prior Application** (for continuation and divisional applications)
*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

_____ A petition, fee and/or response has been filed to extend the term in the pending prior application until
_____ A copy of the petition for extension of time in the **prior** application is attached.

11. **Correspondence Address:**

 X Address all future communications to:

GENENTECH, INC.
Attn: Richard B. Love
1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-5530

Respectfully submitted,
GENENTECH, INC.

Date: January 20, 1999

By: _____

Richard B. Love
Reg. No. 34,659

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881